|author||Jong Seung Kim|
|journal||J. Am. Chem. Soc., Article ASAP DOI: 10.1021/jacs.7b02396(Cover Paper)|
A major challenge in photodynamic cancer therapy (PDT) is avoiding PDT-induced hypoxia, which can lead to cancer recurrence and progression through activation of various angiogenic factors and significantly reduce treatment outcomes. Reported here is an acetazolamide (AZ) conjugated BODIPY photosensitizer (AZ-BPS) designed to mitigate the effects of PDT-based hypoxia by combining the benefits of anti-angiogenesis therapy with PDT. AZ-BPS showed specific affinity to aggressive cancer cells (MDA-MB-231 cells) that overexpress carbonic anhydrase IX (CAIX). It displayed enhanced photo-cytotoxicity compared to a reference compound, BPS, which is an analogous PDT agent that lacks an acetazolamide unit. AZ-BPS also displayed an enhanced in vivo efficacy in a xenograft mouse tumor regrowth model relative to BPS, an effect attributed to inhibition of tumor angiogenesis by both PDT-induced ROS generation and CAIX knockdown. AZ-BPS was evaluated successfully in clinical samples collected from breast cancer patients. We thus believe that the combined approach described here represents an attractive therapeutic approach to targeting CAIX-overexpressing tumors.
« Prev Formation of Triboelectric Series via Atomic Level Surface Fu...Formation of Triboelectric Series via Atomic Level Surface Fu... 2017.05.31by 〈
Vibrational Probes: From Small Molecule Solvatochromism Theor... Next »Vibrational Probes: From Small Molecule Solvatochromism Theor... 2017.04.26by 〉
Designed by sketchbooks.co.kr / sketchbook5 board skin